Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Rapport Therapeutics Inc shares valued at $93,522 were sold by Bredt David on Jun 16 ’25. At $11.00 per share, Bredt David sold 8,500 shares. The insider’s holdings dropped to 443,642 shares worth approximately $4.89 million following the completion of this transaction.
Also, DAVID BREDT purchased 34,000 shares, netting a total of over 380,460 in proceeds.
Before that, Bredt David had sold 8,500 shares from its account. In a trade valued at $81,262, the Chief Scientific Officer traded Rapport Therapeutics Inc shares for $9.56 each. Upon closing the transaction, the insider’s holdings decreased to 8,500 shares, worth approximately $4.99 million.
As published in their initiating research note from Citizens JMP on April 08, 2025, Rapport Therapeutics Inc [RAPP] has been a Mkt outperform. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in early July. As of July 02, 2024, Stifel has initiated its “Buy” rating for RAPP. Earlier on July 02, 2024, Jefferies initiated its rating. Their recommendation was “a Buy” for RAPP stock.
Analyzing RAPP Stock Performance
On last trading session,, Rapport Therapeutics Inc [NASDAQ: RAPP] rose 0.73% to $11.03. The stock’s lowest price that day was $10.655, but it reached a high of $11.31 in the same session. During the last five days, there has been a drop of approximately -8.84%. Over the course of the year, Rapport Therapeutics Inc shares have dropped approximately -37.82%. Shares of the company reached a 52-week high of $19.75 on 01/06/25 and a 52-week low of $6.43 on 03/04/25.
Support And Resistance Levels for Rapport Therapeutics Inc (RAPP)
According to the 24-hour chart, there is a support level at 10.69, which, if violated, would cause prices to drop to 10.34. In the upper region, resistance lies at 11.34. The next price resistance is at 11.65. RSI (Relative Strength Index) is 49.69 on the 14-day chart, showing neutral technical sentiment.
Is Rapport Therapeutics Inc subject to short interest?
Stocks of Rapport Therapeutics Inc saw a sharp rise in short interest on 2025-05-30 jumping by 99561.0 shares to 2.62 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 2.52 million shares. A jump of 3.8% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 17.27 of the overall float, the days-to-cover ratio (short ratio) jumped to 17.27.
Which companies own the most shares of Rapport Therapeutics Inc (RAPP)?
In terms of Rapport Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 35 in the next 12 months, up nearly 219.63% from the previous closing price of $10.95. Analysts anticipate Rapport Therapeutics Inc stock to reach 35 by 2025, with the lowest price target being 35. In spite of this, 2 analysts ranked Rapport Therapeutics Inc stock as Buy at the end of 2025.
